INTEGRATED LABORATORY ABNORMALITY PROFILES OF UPADACITINIB WITH UP TO 4.5 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED IN THE SELECT PHASE 3 PROGRAM

被引：0
|
作者：
Charles-Schoeman, C. [1 ]
Giles, J. T. [2 ]
Lane, N. [3 ]
Choy, E. [4 ]
Furst, D. [5 ]
Vencovsky, J. [6 ]
Wilson, A. G. [7 ]
Burmester, G. R. [8 ]
Shaw, T. [9 ]
Song, Y. [9 ]
Camp, H. [9 ]
Khan, N. [9 ]
Yee, J. [9 ]
Anyanwu, S. [9 ]
Mcinnes, I. [10 ]
机构：
[1] Univ Calif Los Angeles, Rheumatol, Los Angeles, CA USA
[2] Columbia Univ, Rheumatol, New York, NY USA
[3] Univ Calif Davis, Rheumatol, Sacramento, CA USA
[4] Cardiff Univ, CREATE Ctr, Rheumatol, Cardiff, Wales
[5] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[6] Inst Rheumatol, Rheumatol, Prague, Czech Republic
[7] Univ Coll Dublin, Conway Inst, Ctr Arthrit Res, Dublin, Ireland
[8] Charite, Rheumatol, Berlin, Germany
[9] AbbVie Inc, Immunol, N Chicago, IL USA
[10] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.1815
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0128
引用
收藏
页码：72 / 73
页数：2
相关论文
共 50 条
  • [41] A comparison of upadacitinib plus methotrexate and upadacitinib plus other csDMARDs in patients with rheumatoid arthritis: An analysis of two phase 3 studies
    Andrea, Rubbert-Roth
    Joel, Kremer M.
    Filip, Van den Bosch
    Sebastiao, Radominski C.
    Gerd, Burmester R.
    Heidi, Camp S.
    Sebastian, Meerwein
    Mark, Howard
    Song Yanna
    Sheng, Zhong
    Bernard, Combe
    SWISS MEDICAL WEEKLY, 2019, : 8S - 9S
  • [42] A Comparison of Upadacitinib Plus Methotrexate and Upadacitinib Plus Other CsDMARDs in Patients with Rheumatoid Arthritis: An Analysis of Two Phase 3 Studies
    Kremer, Joel
    Van den Bosch, Filip
    Rubbert-Roth, Andrea
    Radominski, Sebastiao
    Burmester, Gerd
    Camp, Heidi
    Meerwein, Sebastian
    Howard, Mark
    Song, Yanna
    Zhong, Sheng
    Combe, Bernard
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [43] A COMPARISON OF UPADACITINIB PLUS METHOTREXATE AND UPADACITINIB PLUS OTHER CSDMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN ANALYSIS OF TWO PHASE 3 STUDIES
    Kremer, Joel
    van den Bosch, Filip
    Rubbert-Roth, Andrea
    Radominski, Sebastiao C.
    Burmester, Gerd Ruediger
    Camp, Heidi
    Meerwein, Sebastian
    Howard, Mark
    Song, Yanna
    Zhong, Sheng
    Combe, Bernard
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 749 - 750
  • [44] A COMPARISON OF UPADACITINIB PLUS METHOTREXATE AND UPADACITINIB PLUS OTHER CSDMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN ANALYSIS OF TWO PHASE 3 STUDIES
    Kremer, Joel M.
    Van den Bosch, Filip
    Rubbert-Roth, Andrea
    Radominski, Sebastiao C.
    Burmester, Gerd R.
    Camp, Heidi S.
    Meerwein, Sebastian
    Howard, Mark
    Song, Yanna
    Zhong, Sheng
    Combes, Bernard
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 11 - 12
  • [45] EXPOSURE-RESPONSE ANALYSES OF UPADACITINIB EFFICACY AND SAFETY IN RHEUMATOID ARTHRITIS - ANALYSES OF PHASE 2 AND 3 STUDIES
    Mohamed, Mohamed-Eslam
    Nader, Ahmed
    Winzenborg, Insa
    Doelger, Eva
    Noertersheuser, Peter
    Pangan, Aileen
    Othman, Ahmed
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 739 - 740
  • [46] Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years
    Charles-Schoeman, Christina
    Giles, Jon T.
    Lane, Nancy E.
    Choy, Ernest
    Daniel E., Furst
    Vencovsky, Jiri
    Wilson, Anthony G.
    Burmester, Gerd R.
    Coombs, Derek
    Penn, Sara K.
    Khan, Nasser
    Yee, Jillian B.
    Rahawi, Kassim
    Mcinnes, Iain B.
    RHEUMATOLOGY AND THERAPY, 2024, 11 (01) : 157 - 175
  • [47] Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme (vol 80, pg 304, 2021)
    Cohen, S. B.
    van Vollenhoven, R. F.
    Winthrop, K. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (05)
  • [48] Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years
    Christina Charles-Schoeman
    Jon T. Giles
    Nancy E. Lane
    Ernest Choy
    Daniel E. Furst
    Jiří Vencovský
    Anthony G. Wilson
    Gerd R. Burmester
    Derek Coombs
    Sara K. Penn
    Nasser Khan
    Jillian B. Yee
    Kassim Rahawi
    Iain B. McInnes
    Rheumatology and Therapy, 2024, 11 : 157 - 175
  • [49] Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND
    van Vollenhoven, Ronald F.
    Hall, Stephen
    Wells, Alvin F.
    Meerwein, Sebastian
    Song, Yanna
    Tanjinatus, Oishi
    Fleischmann, Roy
    RMD OPEN, 2024, 10 (03):
  • [50] RADIOGRAPHIC OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE: RESULTS AT 2 YEARS FROM THE SELECT-COMPARE AND SELECT-EARLY STUDIES
    Peterfy, C.
    Strand, V.
    Genovese, M. C.
    Friedman, A.
    Enejosa, J. J.
    Hall, S.
    Mysler, E.
    Durez, P.
    Baraliakos, X.
    Shaw, T.
    Song, Y.
    Li, Y.
    Song, I. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 326 - 327
12345